AI in Biotech Research: Boon or Bane?
Philip Crowley
November 29, 2024
Is Artificial Intelligence a Boon Or a Bane? Just a few years ago, discussions about artificial intelligence (“AI”) were mostly
Is Artificial Intelligence a Boon Or a Bane? Just a few years ago, discussions about artificial intelligence (“AI”) were mostly
Cybersecurity Challenges in Biotech: Why Your Data is a Prime Target In the first quarter of 2024, weekly cyberattacks against
The BioNJ 31st Annual Dinner Meeting and Innovation Celebration, held on February 8, 2024, was a significant event that showcased
Key Highlights: · Strategic Shift: CRISPR Therapeutics is pivoting from cancer drug development to cell-based medicines for autoimmune
It’s not just your hometown physician’s travel bag anymore! In the dynamic field of life sciences, cell and gene therapy
We live in an extraordinary time. It’s a time where technology in life sciences is peeling back the curtain on
Securing Your Intellectual Property in the Age of Discovery Is artificial intelligence (AI) a boon or bane, or perhaps a bit
Recently proposed Federal legislation would have a very damaging effect on the biotech industry. Those are the conclusions of a recent
Last week I had the opportunity to attend the BioMedical Engineering Day at Stevens Institute of Technology in Hoboken, New Jersey. It
Patents For Humanity Program Improvement Act The Patents for Humanity Program Improvement Act, H.R. 7259, was introduced on June 18th,